fda proposes to lower the bar on alzheimer's d, page-9

I guess the FDA can shorten trial times as reliable biomarkers become known, through the likes of the fantastic CSIRO´s AIBL study, and the fact now there are drugs emerging which can prove disease modification, the most complete being Prana´s PBT2, with synaps repair, iron clearance, neuron regrowth, restoration of dendretic spines , control of hyperphosphorylation kinase enzyme GSK3, inhibition of protein misfolding, clearance of plaqes, clearance and prevention of Tau tangles etc, all through the ability of being able to capture essential metals trapped in plaques outside neurons, and reposition them where they are needed for normal function back inside neurons.
As I recall the Lindquist paper also indicated an ability of MPACs to move these metals around inside neurons also.
With these new guidelines, and an ability to demonstrate efficacy gains, I see no reason why trials should not be quick for these drugs.